1. Pink Sheet

Alzheimer’s Biomarker Development Hampered By ‘Limited’ Commercial Incentives

 
• By Cathy Kelly

Eli Lilly executive suggests the public sector may need to come up with a solution to drive innovation if the private sector does not do so.

Alzheimers_677117191_Atthapon-Raksthaput_1200.jpg

Development of biomarkers for Alzheimer’s disease is critically important to advancing innovative payment models for treatments as well as care models for patients with the disease, according to Eli Lilly & Co.’s Phyllis Ferrell, head of external engagement for Alzheimers and neurodegeneration.

But “biomarkers are an objective way of measuring response to therapy that we don’t have today,” Ferrell pointed out during a Duke Margolis webinar on reimbursement for Alzheimer’s drugs held last month

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Access

More from Pink Sheet

US FDA COVID-19 Booster Strategy May Not Be As Controversial As It Seems

 
• By Michael McCaughan

US FDA Commissioner Martin Makary’s call for placebo-controlled trials to confirm the efficacy of COVID-19 boosters is drawing a lot of criticism, but former Commissioner Robert Califf also supported the idea.

EU Moment Of Truth For Obe-Cel And 10 Other New Medicines

 
• By Neena Brizmohun

Autolus’s CAR T therapy obe-cel is among the medicines that are this week due for an opinion by the European Medicines Agency on whether they should be marketed in the EU.

Blenrep’s Revival Gains Steam: EMA Decision Imminent As Japan Approves New Regimen

 
• By Neena Brizmohun

The European Medicines Agency is due to decide whether GSK’s previously approved multiple myeloma drug that was withdrawn from the market in 2022 should be approved again for use in combination with BorDex or PomDex. Meanwhile, Japan today became the second major regulator to approve the Blenrep combinations.